Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Get Rating) by 39.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,173 shares of the company’s stock after purchasing an additional 5,392 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in ImmunityBio were worth $97,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. MetLife Investment Management LLC boosted its stake in shares of ImmunityBio by 72.1% in the third quarter. MetLife Investment Management LLC now owns 44,059 shares of the company’s stock valued at $219,000 after purchasing an additional 18,454 shares during the period. ProShare Advisors LLC increased its holdings in shares of ImmunityBio by 6.2% in the 3rd quarter. ProShare Advisors LLC now owns 42,697 shares of the company’s stock valued at $212,000 after acquiring an additional 2,510 shares during the period. Liberty One Investment Management LLC increased its stake in ImmunityBio by 149.4% in the 3rd quarter. Liberty One Investment Management LLC now owns 30,122 shares of the company’s stock valued at $150,000 after buying an additional 18,042 shares during the period. Oracle Investment Management Inc. acquired a new position in ImmunityBio in the 3rd quarter valued at $1,567,000. Finally, Mayflower Financial Advisors LLC acquired a new position in ImmunityBio in the 4th quarter valued at $84,000. 9.86% of the stock is currently owned by institutional investors and hedge funds.
ImmunityBio Trading Down 7.6 %
ImmunityBio stock opened at $5.92 on Wednesday. ImmunityBio, Inc. has a 52 week low of $1.21 and a 52 week high of $7.80. The firm’s 50-day simple moving average is $2.21 and its 200 day simple moving average is $3.92.
ImmunityBio, Inc is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory.
- Get a free copy of the StockNews.com research report on ImmunityBio (IBRX)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX – Get Rating).
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.